Drug updated on 4/17/2024
| Dosage Form | Injection (intravenous: 100 mg/4 mL [25 mg/mL] or 400 mg/16 mL [25 mg/mL] in a single-dose vial) |
| Drug Class | Vascular endothelial growth factor inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
- Indicated for the treatment of metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
- Indicated for the treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
- Indicated for the treatment of recurrent glioblastoma in adults.
- Indicated for the treatment of metastatic renal cell carcinoma in combination with interferon-alfa.
- Indicated for the treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.
- Indicated for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection; in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens; in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinumsensitive recurrent disease.
Summary
- Bevacizumab-awwb (Mvasi) is indicated for the treatment of various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma in adults, metastatic renal cell carcinoma, persistent or recurrent cervical cancer, and epithelial ovarian/fallopian tube/primary peritoneal cancer. It is often used in combination with other chemotherapy drugs.
- A total of 29 systematic reviews/meta-analyses were reviewed to gather information about Mvasi's safety and effectiveness compared to other drugs across different indications and populations.
- In treating metastatic colorectal cancer (mCRC), Mvasi showed stronger anti-tumor activity when combined with chemotherapy but did not consistently show significant long-term survival improvements. However, it was associated with increased rates of severe hypertension and vascular-related adverse events.
- For Non-Squamous Non-Small Cell Lung Cancer (NSCLC), a combination treatment involving atezolizumab plus Mvasi demonstrated good efficacy but also had a considerable incidence of any grade and high-grade adverse events, requiring close monitoring.
- When treating advanced hepatocellular carcinoma (HCC), atezolizumab combined with Mvasi significantly improved survival metrics, although many patients experienced serious side effects that were grade 3 or above.
- In cases of recurrent glioblastoma in adults, evidence supporting significant improvement from using Mvasi was limited due to the lack of established predictive or prognostic biomarkers for its use on this type of tumor. The drug’s safety profile wasn’t extensively detailed either within this context.
- In cases of ovarian cancers, such as epithelial ovarian/fallopian tube/primary peritoneal types, the drug has shown efficacy, especially when paired up with carboplatin and paclitaxel, leading to better overall response rates and progression-free survivals, particularly in platinum-sensitive recurring diseases despite increasing risks of specific adversities like hypertension and proteinuria.
- Mvasi's effectiveness and safety vary significantly across different population groups, cancer types, and treatment lines. Special attention to patient characteristics, such as disease stage and previous treatment regimens, is crucial when considering Mvasi as a therapeutic option.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Mvasi (bevacizumab-awwb) Prescribing Information. | 2023 | Amgen, Inc., Thousand Oaks, CA |